Intrequency of "pure" GAD: Impact of psychiatric comorbidity on clinical course

被引:59
作者
Bruce, SE [1 ]
Machan, JT [1 ]
Dyck, I [1 ]
Keller, MB [1 ]
机构
[1] Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02906 USA
关键词
adult; anxiety disorders diagnosis; anxiety disorders psychology; comorbidity; follow-up studies; longitudinal studies; prospective studies;
D O I
10.1002/da.1070
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
The widespread occurrence of psychiatric comorbidity among patients with generalized anxiety disorder (GAD) has been well documented. However, there is a paucity of studies examining the impact comorbid disorders have on the clinical course of GAD. In this study, 179 patients with GAD at intake, 12 patients with a past history of GAD, and 109 patients who subsequently onset a first episode of GAD during the course of follow-up were followed for 8 years in this naturalistic, prospective study of anxiety disorders. Results indicate that comorbid anxiety, mood, and substance use disorders are very common with GAD and increased during follow-up. For example, 39% of participants with GAD also had a comorbid diagnosis of major depressive disorder at intake and increased to 65% at 4 years and 74% at the 8-year follow-zip. Inspection of "pure" cases of GAD indicated that out of 20 patients with GAD alone at intake, all but 1 went on to develop some comorbidity. Results also indicate that being in episode of comorbid MDD or panic disorder with agoraphobia decreased the probability that a subject would remit from their GAD. The findings highlight the need for such long-term, prospective research since results show that patients with GAD at intake bad increasing risk for developing other mental disorders during subsequent follow-ups. Additionally, results of such high comorbidity and the impact of these comorbid disorders on the clinical course of GAD should have a notable impact on research into the treatment of GAD. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 24 条
[1]   Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders [J].
Altamura, AC ;
Pioli, R ;
Vitto, M ;
Mannu, P .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (04) :239-245
[2]   THE NATURAL-HISTORY OF ANXIETY DISORDERS [J].
ANGST, J ;
VOLLRATH, M .
ACTA PSYCHIATRICA SCANDINAVICA, 1991, 84 (05) :446-452
[3]   CO-MORBIDITY AND DEPRESSION AMONG THE ANXIETY DISORDERS - ISSUES IN DIAGNOSIS AND CLASSIFICATION [J].
BARLOW, DH ;
DINARDO, PA ;
VERMILYEA, BB ;
VERMILYEA, J ;
BLANCHARD, EB .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1986, 174 (02) :63-72
[4]  
Blazer D., 1991, PSYCHIAT DISORDERS A, P180
[5]   COMORBIDITY AMONG ANXIETY DISORDERS - IMPLICATIONS FOR TREATMENT AND DSM-IV [J].
BROWN, TA ;
BARLOW, DH .
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1992, 60 (06) :835-844
[6]  
BROWN TA, 1994, AM J PSYCHIAT, V151, P1272
[7]   The infrequency of ''pure culture'' diagnoses among the anxiety disorders [J].
Goldenberg, IM ;
White, K ;
Yonkers, K ;
Reich, J ;
Warshaw, MG ;
Goisman, RM ;
Keller, MB .
JOURNAL OF CLINICAL PSYCHIATRY, 1996, 57 (11) :528-533
[8]   Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS) [J].
Judd, LL ;
Kessler, RC ;
Paulus, MP ;
Zeller, PV ;
Wittchen, HU ;
Kunovac, JL .
ACTA PSYCHIATRICA SCANDINAVICA, 1998, 98 :6-11
[9]  
KELLER MB, 1987, ARCH GEN PSYCHIAT, V44, P540
[10]   REMISSION AND RELAPSE IN SUBJECTS WITH PANIC DISORDER AND PANIC WITH AGORAPHOBIA - A PROSPECTIVE SHORT-INTERVAL NATURALISTIC FOLLOW-UP [J].
KELLER, MB ;
YONKERS, KA ;
WARSHAW, MG ;
PRATT, LA ;
GOLLAN, JK ;
MASSION, AO ;
WHITE, K ;
SWARTZ, AR ;
REICH, J ;
LAVORI, PW .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1994, 182 (05) :290-296